Literature DB >> 26032252

Potentially inappropriate prescribing in older patients admitted to psychiatric hospital.

Sara Rongen1,2, Cornelis Kramers2,3,4, Denis O'Mahony5,6, Ton B Feuth7, Marcel G M Olde Rikkert8,9, Amir I A Ahmed1,2,8.   

Abstract

OBJECTIVES: The objectives of this study are to determine the prevalence of potentially inappropriate prescribing including potentially inappropriate medications (PIMs) and potential prescription omissions (PPOs) and to assess related risk factors in older people with major psychiatric illness.
METHODS: This was a cross-sectional study of older patients hospitalized in a psychiatric hospital (n = 164; mean age 74.9 ± 7.3 years; 62% female). The primary endpoint was the prevalence of participants receiving PIMs and PPOs, which was assessed by using the Beers criteria 2012 and the screening tool of older person's potentially inappropriate prescriptions (STOPP) and screening tool of alert doctors to the right treatment (START) criteria. Univariate and multivariate logistic regression was used to assess significant risk factors for PIMs in this population.
RESULTS: A total of 1269 drugs were prescribed to included patients (range: 0-19 drugs/day). PIMs were identified in 47% and 79% of participants, based on the Beers 2012 and STOPP criteria, respectively. Most PIMs (70%) concerned psychotropic drugs. The STOPP criteria identified more PIMs (331) than the Beers criteria 2012 (199). According to the START criteria, 59% of participants had PPOs. The number of prescribed medications was significantly associated with the occurrence of PIMs according to the Beers 2012 [OR 1.2 (95% CI 1.1-1.3)] and STOPP [OR 1.5 (95% CI 1.3-1.8)] criteria.
CONCLUSION: Potentially inappropriate prescribing, as identified by the Beers and STOPP/START criteria, is highly prevalent among older patients hospitalized with major psychiatric illness. However, the focus on psychotropic drugs prescription without taking into account the benefit of these drugs to individual patients may limit the application of the Beers and STOPP criteria in psychiatric hospitals.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Beers criteria; Older patients; STOPP/START criteria; potentially inappropriate prescribing; psychiatric hospital

Mesh:

Year:  2015        PMID: 26032252     DOI: 10.1002/gps.4302

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  6 in total

Review 1.  Management of Behavioral and Psychological Symptoms of Dementia.

Authors:  Laurel J Bessey; Art Walaszek
Journal:  Curr Psychiatry Rep       Date:  2019-07-01       Impact factor: 5.285

2.  Clinical pharmacist interventions in ambulatory psychogeriatric patients with excessive polypharmacy.

Authors:  Matej Stuhec; Kaja Zorjan
Journal:  Sci Rep       Date:  2022-07-06       Impact factor: 4.996

3.  Pharmacist intervention acceptance for the reduction of potentially inappropriate drug prescribing in acute psychiatry.

Authors:  Sophia Hannou; Pierre Voirol; André Pannatier; Marie-Laure Weibel; Farshid Sadeghipour; Armin von Gunten; Jean-Frédéric Mall; Isabella De Giorgi Salamun
Journal:  Int J Clin Pharm       Date:  2017-09-13

4.  Potentially inappropriate medications in hospitalized older patients: a cross-sectional study using the Beers 2015 criteria versus the 2012 criteria.

Authors:  Xiaolin Zhang; Shuang Zhou; Kunming Pan; Xinran Li; Xia Zhao; Ying Zhou; Yimin Cui; Xinmin Liu
Journal:  Clin Interv Aging       Date:  2017-10-12       Impact factor: 4.458

5.  Potentially Inappropriate Medications in a Psychogeriatric Inpatient Ward: An Audit Based on Beers Criteria.

Authors:  Isabelle Moebs; Esther Abeln; Annalise Siefert; Yoram Barak
Journal:  Neurol Ther       Date:  2020-04-17

6.  Impact of clinical pharmacist's interventions on pharmacotherapy management in elderly patients on polypharmacy with mental health problems including quality of life: A prospective non-randomized study.

Authors:  Matej Stuhec; Nika Bratović; Aleš Mrhar
Journal:  Sci Rep       Date:  2019-11-14       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.